Novel therapies for hepatitis C: insights from the structure of the virus
- PMID: 21942423
- DOI: 10.1146/annurev-med-042010-085715
Novel therapies for hepatitis C: insights from the structure of the virus
Abstract
For the first time since the discovery of the hepatitis C virus (HCV), therapeutic options for hepatitis C have expanded. Several agents directly effective against HCV are now in development, including both direct-acting antiviral agents (DAAs) and host cofactor inhibitors. DAAs have been developed to inhibit several HCV proteins, including the NS3/4A serine protease, the NS5B RNA polymerase, NS5A, and NS4B. Host cofactor inhibitors include, but are not limited to, cyclophilin inhibitors, miR122 antagonists, and statins. Development of these agents represents a major advance in HCV therapeutics. This review provides a guide to HCV drugs in various stages of development, including an introduction to their mechanism of action, state of clinical development, efficacy, and side effects.
Similar articles
-
Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Expert Opin Investig Drugs. 2013 Sep;22(9):1107-21. doi: 10.1517/13543784.2013.806482. Epub 2013 Jun 4. Expert Opin Investig Drugs. 2013. PMID: 23735127 Review.
-
Hepatitis C virus resistance to protease inhibitors.J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. J Hepatol. 2011. PMID: 21284949 Review.
-
Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x. Liver Int. 2012. PMID: 22212577 Review.
-
The race for interferon-free HCV therapies: a snapshot by the spring of 2012.Rev Med Virol. 2012 Nov;22(6):392-411. doi: 10.1002/rmv.1727. Epub 2012 Aug 30. Rev Med Virol. 2012. PMID: 22936636 Review.
-
Targets for antiviral therapy of hepatitis C.Semin Liver Dis. 2014 Feb;34(1):9-21. doi: 10.1055/s-0034-1371006. Epub 2014 Apr 29. Semin Liver Dis. 2014. PMID: 24782254 Review.
Cited by
-
Incorporating Intracellular Processes in Virus Dynamics Models.Microorganisms. 2024 Apr 30;12(5):900. doi: 10.3390/microorganisms12050900. Microorganisms. 2024. PMID: 38792730 Free PMC article. Review.
-
In Silico Drug Discovery for Treatment of Virus Diseases.Adv Exp Med Biol. 2022;1368:73-93. doi: 10.1007/978-981-16-8969-7_4. Adv Exp Med Biol. 2022. PMID: 35594021
-
Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment.Clin Liver Dis (Hoboken). 2014 Apr 1;3(3):65-68. doi: 10.1002/cld.332. eCollection 2014 Mar. Clin Liver Dis (Hoboken). 2014. PMID: 30992888 Free PMC article. No abstract available.
-
Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist.Infect Agent Cancer. 2017 Feb 7;12:12. doi: 10.1186/s13027-017-0119-8. eCollection 2017. Infect Agent Cancer. 2017. PMID: 28191032 Free PMC article.
-
Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free Regimen.ACG Case Rep J. 2017 Feb 1;4:e16. doi: 10.14309/crj.2017.16. eCollection 2017. ACG Case Rep J. 2017. PMID: 28184373 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
